Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : PB2452
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : SFJ Pharmaceuticals
Deal Size : $120.0 million
Deal Type : Collaboration
PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals® for PB2452
Details : The collaboration with SFJ provides PhaseBio with substantial funding to continue the rapid advancement of lead program, PB2452.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 10, 2020
Lead Product(s) : PB2452
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : SFJ Pharmaceuticals
Deal Size : $120.0 million
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?